STALICLA Employee Directory
Biotechnology ResearchGeneva, Switzerland11-50 Employees
STALICLA is a Swiss clinical-stage biotechnology company focusing on Neuro Precision Medicine for neurodevelopmental and neuropsychiatric disorders. It aims to tailor therapies to specific patient subgroups, such as those with autism spectrum disorder, using an integrated, multi-omics approach to identify candidate drugs, with STP1 advancing toward Phase 2 trials. In the realm of Substance Use Disorder, the company collaborates with the National Institute on Drug Abuse (NIDA) to move STP7, for cocaine use disorder, into Phase 3 trials. Based in Geneva, Switzerland, STALICLA operates in the biotechnology research sector, pursuing precision medicines for brain disorders. As a small to mid-sized biotech company, it sits within the Swiss life sciences landscape focusing on neurodevelopmental and neuropsychiatric indications with a pipeline spanning Phase 2 and Phase 3 trials. Recent leadership developments include the appointment of Dr. Purnanand Sarma as Chair of the Board in July 2024.
1-888-653-2347 
support@leadiq.com 
